Blinded Diagnostics Appoints Patricia H. Averette as VP, Business Development

Blinded Diagnostics Appoints Patricia H. Averette as VP, Business Development

Saddle Brook, NJ, January 2, 2013:  Blinded Diagnostics today announced the expansion of their business development efforts by appointing Patricia H. Averette as the new Vice President of Business Development.  Patty,  a seasoned health care professional with a solid background in Hematology Lab Diagnostics, Technical Service and Sales, will be working from Charlotte, North Carolina to provide point of care diagnostics solutions to pharmaceutical and biopharmaceutical clients in the Southeastern US.

"We are glad to add Patty to the team, she will be introducing our services to the Research Triangle Park area and Southeastern biotech companies interested in same day lab test results for clinical trials" said Steve Karuppan, CEO of Blinded Diagnostics.  He added that "Patty's experience is a plus for Blinded Diagnostics because she has first-hand knowledge in point of care diagnostics solutions."

Patty has a successful track record in Strategic Sales and Business Development focusing on innovative and disruptive technologies. She has held management roles in Technical Service, Clinical Informatics, along with Product Management and Technical Sales with Abbott Diagnostics, Inc. She achieved a BS in Medical Technology from the University of North Carolina, Greensboro and served as the Assistant Supervisor of Hematology at the Carolinas Medical Center in Charlotte, NC. Her Medical Device experience includes Point-of-Care testing and EMR experience. She brings a strong knowledge of GMP and regulatory practices in all scientific disciplines.

About Blinded Diagnostics
A pioneering contract service organization specializing in sourcing and supporting point of care diagnostic test platforms that provide same day lab test results for pharmaceutical clinical trials. Blinded Diagnostics has a successful track record of expertise in meeting large pharmaceutical company testing needs with thorough knowledge of the protocol design, Investigator training and firmware encryption. As an innovator with partners in point-of-care diagnostics, Blinded Diagnostics is at the forefront of a paradigm shift that brings flexibility and efficiency for trial sponsors.
www.blindeddiagnostics.com

Contact: Steve Karuppan, CEO
Blinded Diagnostics  LLC
Phone: (201) 291-2822
[email protected]

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.